Qingqing Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qingqing Cai has a total of 768 co-authors. Here are the top co-authors by number of shared publications:
- Yi Xia
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China
36 shared publications - Man Nie
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China
31 shared publications Jun Cai
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China
28 shared publicationsYu Fang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, China
22 shared publications- Jun Cai
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
21 shared publications - Yuchen Zhang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China
21 shared publications
Latest Publications
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline
PURPOSE: To provide evidence-based recommendations on first- and subsequent-line systemic therapy, maintenance therapy, locoregional consolidation, and salvage local therapy for patients with recurrent and/or metastatic nasopharyngeal carcinoma (NPC). METHODS: A multidisciplinary Expert Panel convened by CSCO and ASCO reviewed evidence from randomized trials, meta-analyses, systematic reviews, prospective and retrospective studies, and clinical experience. The guideline was informed by a systematic literature review and consensus-based interpretation of efficacy, safety, feasibility, and patient-centered outcomes across scenarios. Outcomes included overall and progression-free survival, response and disease control rates, toxicity, and quality of life. RESULTS: Evidence supports platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients. Evidence also supports maintenance strategies after disease control, while treatment selection depends on prior treatment, disease extent, patient fitness, resource availability, and preferences. Selected responders may receive locoregional consolidation radiotherapy or oral maintenance chemotherapy. For isolated locoregional recurrence amenable to local therapy, options include salvage surgery and re-irradiation. RECOMMENDATIONS: Chemotherapy plus a PD-1 inhibitor, followed by maintenance PD-1 inhibition for up to 2 years, should be offered first-line to appropriate patients with recurrent and/or metastatic NPC. Chemotherapy alone may be offered when immunotherapy is unsuitable or declined. Selected patients responding to first-line chemotherapy may receive oral maintenance chemotherapy or locoregional consolidation intensity-modulated radiotherapy. Salvage surgery or re-irradiation is recommended for appropriately selected patients with isolated locoregional recurrence. Subsequent-line options include chemotherapy, PD-1 inhibitors, and antibody-drug conjugates. Treatment should be individualized according to disease setting, prior therapy, expected toxicities, availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care, where available, should accompany active anticancer treatment for advanced, incurable disease. Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer .
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline
PURPOSE: To provide evidence-based recommendations on first- and subsequent-line systemic therapy, maintenance therapy, locoregional consolidation, and salvage local therapy for patients with recurrent and/or metastatic nasopharyngeal carcinoma (NPC). METHODS: A multidisciplinary Expert Panel convened by CSCO and ASCO reviewed evidence from randomized trials, meta-analyses, systematic reviews, prospective and retrospective studies, and clinical experience. The guideline was informed by a systematic literature review and consensus-based interpretation of efficacy, safety, feasibility, and patient-centered outcomes across scenarios. Outcomes included overall and progression-free survival, response and disease control rates, toxicity, and quality of life. RESULTS: Evidence supports platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients. Evidence also supports maintenance strategies after disease control, while treatment selection depends on prior treatment, disease extent, patient fitness, resource availability, and preferences. Selected responders may receive locoregional consolidation radiotherapy or oral maintenance chemotherapy. For isolated locoregional recurrence amenable to local therapy, options include salvage surgery and re-irradiation. RECOMMENDATIONS: Chemotherapy plus a PD-1 inhibitor, followed by maintenance PD-1 inhibition for up to 2 years, should be offered first-line to appropriate patients with recurrent and/or metastatic NPC. Chemotherapy alone may be offered when immunotherapy is unsuitable or declined. Selected patients responding to first-line chemotherapy may receive oral maintenance chemotherapy or locoregional consolidation intensity-modulated radiotherapy. Salvage surgery or re-irradiation is recommended for appropriately selected patients with isolated locoregional recurrence. Subsequent-line options include chemotherapy, PD-1 inhibitors, and antibody-drug conjugates. Treatment should be individualized according to disease setting, prior therapy, expected toxicities, availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care, where available, should accompany active anticancer treatment for advanced, incurable disease. Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer .
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
This file contains the protocol and statistical analysis plan.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
This file contains the protocol and statistical analysis plan.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S2 shows percentage change from baseline in target lesion size over time for individual patients in the TPGC cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S2 shows percentage change from baseline in target lesion size over time for individual patients in the TPGC cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S3 depicts Kaplan–Meier curves of progression-free survival according to PD-L1 expression status in the TPGC cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S3 depicts Kaplan–Meier curves of progression-free survival according to PD-L1 expression status in the TPGC cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S4 shows cell-free EBV DNA dynamics of the TP cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S4 shows cell-free EBV DNA dynamics of the TP cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S5 shows cell-free EBV DNA dynamics of the TPGC cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S5 shows cell-free EBV DNA dynamics of the TPGC cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S6 depicts Kaplan–Meier curves of progression-free survival according to EBV DNA dynamics-based group in patients from the two cohorts.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Figure S6 depicts Kaplan–Meier curves of progression-free survival according to EBV DNA dynamics-based group in patients from the two cohorts.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S1 shows the representativeness of study participants.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S1 shows the representativeness of study participants.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S3 summarizes clinical trials that explore PD-1 blockade combined with GP chemotherapy in R/M NPC.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S3 summarizes clinical trials that explore PD-1 blockade combined with GP chemotherapy in R/M NPC.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S2 details the information of recruitment sites.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial
Table S2 details the information of recruitment sites.